Tuesday, January 3, 2017

FDA nails a third Wockhardt plant with a warning letter

January 3, 2017 | By Eric Palmer
The FDA sidelined U.S. biotech Cempra’s new generation antibiotic with a complete response letter last week over safety concerns, but also because of issues it has with the Wockhardt plant making the API for it. 
Post a Comment